Floatz logo

azd0530

Parkinson Disease Psychosis

King's College LondonEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Parkinson Disease Psychosis cohort.

Asset / SponsorPhaseRating
Acp-103
Humanis Saglık Anonim Sirketi
Phase 4BB
Ulotaront
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2B
agb101
Johns Hopkins University
Phase 2CCC
Iloperidone
Vanda Pharmaceuticals
Phase 2CCC
fb418
1ST Biotherapeutics, Inc.
Phase 1CC
ly03017
Luye Pharma Group Ltd.
Phase 1CC

Same molecule, other indications

azd0530 is also rated in:

prostate cancerDormant
B
Indicative ·
62 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
58 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →